The antibody drug, Zinplava, was first approved by the regulator in 2016 to prevent the recurrence of Clostridioides difficile infections (CDI). CDI is generally caused by prolonged use of antibiotics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback